Skip Navigation

Journal of Biochemistry 2005 137(3):339-347; doi:10.1093/jb/mvi042
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Umehara, T.
Right arrow Articles by Nishikawa, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Umehara, T.
Right arrow Articles by Nishikawa, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 The Japanese Biochemical Society

Regular Paper

Rational Design of Dual-Functional Aptamers That Inhibit the Protease and Helicase Activities of HCV NS3

Takuya Umehara1,2, Kotaro Fukuda1,2, Fumiko Nishikawa1, Michinori Kohara3, Tsunemi Hasegawa2 and Satoshi Nishikawa1,*

1 Institute for Biological Resources and Functions, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki 305-8566; 2 Department of Material and Biological Chemistry, Faculty of Science, Yamagata University, Yamagata 990-8560; and 3 Tokyo Metropolitan Institute of Medical Science, Bunkyo-ku, Tokyo 113-8613

* To whom correspondence should be addressed. Tel: +81-298-61-6085, Fax: +81-298-61-6159, E-mail: satoshi-nishikawa{at}aist.go.jp

ABSTRACT

The hepatitis C virus (HCV) non-structural protein 3 (NS3) is a multifunctional enzyme with protease and helicase activities. It is essential for HCV proliferation and is therefore a target for anti-HCV drugs. Previously, we obtained RNA aptamers that inhibit either the protease or helicase activity of NS3. During the present study, these aptamers were used to create advanced dual-functional (ADD) aptamers that were potentially more effective inhibitors of NS3 activity. The structural domain of the helicase aptamer, #5{Delta}, was conjugated via an oligo(U) tract to the 3'-end of the dual functional aptamer NEO-III-14U or the protease aptamer G9-II. The spacer length was optimized to obtain two ADD aptamers, NEO-35-s41 and G925-s50; both were more effective inhibitors of NS3 protease/helicase activity in vitro, especially the helicase, with a four- to five-fold increase in inhibition compared with #5 and NEO-III-14U. Furthermore, G925-s50 effectively inhibited NS3 protease activity in living cells and HCV replication in vitro. Overall, we have demonstrated rational RNA aptamer design based on features of both aptamer and target molecules, as well as successfully combining aptamer function and increasing NS3 inhibition.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
T. Shiohara, H. Saito, and T. Inoue
A designed RNA selection: establishment of a stable complex between a target and selectant RNA via two coordinated interactions
Nucleic Acids Res., February 1, 2009; 37(3): e23 - e23.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
W. James
Aptamers in the virologists' toolkit
J. Gen. Virol., February 1, 2007; 88(2): 351 - 364.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.